



-73-

CLAIMS

1. A compound according to the general Formula (Ia) or the general Formula (Ib)

5




the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, wherein :


10 R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;

p is an integer equal to 1, 2 or 3;

R^2 is hydrogen; alkyl; hydroxy; thio; alkyloxy optionally substituted with

amino or mono or di(alkyl)amino or a radical of formula 
 wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰ and t is an integer equal to 1 or 2
 15 and the dotted line represents an optional bond; alkyloxyalkyloxy;
 alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be
 substituted with one or two substituents each independently be selected
 from alkyloxy or Ar or Het or morpholinyl or 2-oxopyrrolidinyl; Ar, Het

-74-



or a radical of formula $(\text{CH}_2)_t\text{-N-}$ wherein Z is CH_2 , CH-R^{10} , O, S, N-R^{10} ; t is an integer equal to 1 or 2; and the dotted line represents an optional bond;


R^3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

5 q is an integer equal to zero, 1, 2, 3 or 4 ;

X is a direct bond or CH_2 ;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolynyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings optionally being substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl;



R^6 is hydrogen or a radical of formula $(\text{CH}_2)_s$ wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5 ; and R^{11} is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or two vicinal R^{11} radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl;

R^7 is hydrogen, alkyl, Ar or Het ;

R^8 is hydrogen or alkyl ;

25 R^9 is oxo ; or


R^8 and R^9 together form the radical $-\text{CH}=\text{CH}-\text{N}=\text{}$;

R^{10} is hydrogen, alkyl, hydroxyl, aminocarbonyl, mono- or di(alkyl)aminocarbonyl, Ar, Het, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)- , Ar-C(=O)- ;

30 alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6

-75-

- carbon atoms ; or is a a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo ;
- 5 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, alkylcarbonyl, aminocarbonyl, morpholinyl and
- 10 mono- or dialkylaminocarbonyl ;
- Het is a monocyclic heterocycle selected from the group of N-phenoxypiperidiny, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, isoquinolinyl,
- 15 1,2,3,4-tetrahydroisoquinolinyl, quinoxalinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the
- 20 group of halo, hydroxy, alkyl or alkyloxy;
- halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and
- haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted
- 25 with one or more halo-atoms;





provided that when R⁷ is hydrogen then the radical may also be placed in position 3 of the quinoline ring.

2. A compound according to claim 1 provided that when R⁶ is other than hydrogen then
- 30 R⁷ is hydrogen and when R⁷ is other than hydrogen then R⁶ is hydrogen.

3. A compound according to claim 1 or 2 wherein R² is hydrogen; alkyl; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula

-76-


 wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰ and t is an integer equal to 1 or 2 and the dotted line represents an optional bond; mono or di(alkyl)amino; Ar; Het or a

radical of formula
 
 wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰; t is an integer equal 1 or 2; and the dotted line represents an optional bond.


5

4. A compound according to any one of the preceding claims wherein R³ is naphthyl, phenyl or Het, each optionally substituted with 1 or 2 substituents, that substituent being a halo or haloalkyl.

10 5. A compound according to any one of the preceding claims wherein q is equal to 1.

6. A compound according to any one of the preceding claims wherein R⁴ and R⁵ each independently are hydrogen or alkyl.


15 7. A compound according to any one of the preceding claims wherein R⁶ is hydrogen or




a radical of formula
 wherein s is an integer equal to zero or 1; r is an integer equal to 1 or 2.

20 8. A compound according to any one of the preceding claims wherein R⁷ is hydrogen or Ar.

9. A compound according to claim 1 wherein R¹ is hydrogen, halo, alkyl or Het; R² is alkyl, alkyloxy optionally substituted with mono or di(alkyl)amino or a radical of

formula
 
 wherein Z is CH₂, CH-R¹⁰, O, N-R¹⁰, t is an integer equal to 1 or 2, and R¹⁰ is hydrogen, alkyl, hydroxyl, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)-; Ar; Het; a radical of formula

25


 wherein Z is CH₂, CH-R¹⁰, O, N-R¹⁰; t is an integer equal to 1 or 2,

-77-


wherein R^{10} is hydrogen, alkyl, hydroxyl, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)-; R^3 is Ar or Het, each optionally substituted with 1 or 2 substituents that substituent being a halo; R^4 and R^5 are each alkyl; R^6 is hydrogen, phenyl, benzyl or 4-methylbenzyl; R^7 is hydrogen or phenyl; R^8 is hydrogen; R^9 is oxo.

10. A compound according to claim 1 wherein


R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;

10 p is an integer equal to 1, 2 or 3;

R^2 is hydrogen; alkyl; hydroxy; thio; alkyloxy optionally substituted with

amino or mono or di(alkyl)amino or a radical of formula 

wherein Z is CH_2 , $CH-R^{10}$, O, S, $N-R^{10}$ and t is an integer equal to 1 or 2 and the dotted line represents an optional bond; alkyloxyalkoxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted with one or two substituents each independently be selected from alkyloxy or Ar or Het or morpholinyl or 2-oxopyrrolidinyl; Het or

15 a radical of formula  wherein Z is CH_2 , $CH-R^{10}$, O, S, $N-R^{10}$; t is an integer equal to 1 or 2; and the dotted line represents an optional bond;

20 R^3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

q is an integer equal to zero, 1, 2, 3 or 4 ;


X is a direct bond;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

25 R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings optionally being substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl;

30

-78-



- R⁶** is a radical of formula $(CH_2)_s$ wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and **R¹¹** is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal **R¹¹** radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl;
- R⁷** is hydrogen, alkyl, Ar or Het;
- R⁸** is hydrogen or alkyl;
- R⁹** is oxo; or
- R⁸ and R⁹** together form the radical $-CH=CH-N=$;
- R¹⁰** is hydrogen, alkyl, aminocarbonyl, mono- or di(alkyl)aminocarbonyl, Ar, Het, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)-;
- alkyl** is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo;
- Ar** is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxy carbonyl, alkyl carbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl;
- Het** is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothieryl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl; each monocyclic and

-79-

bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy ;

halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and

haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted with one or more halo-atoms.

11. A compound according to any one of the preceding claims wherein the compound is a compound of formula (Ia).


12. A compound according to any one of the preceding claims for use as a medicine.

13. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 11.

14. Use of a compound according to any one of claims 1 to 11 or a composition according to claim 13 for the manufacture of a medicament for the treatment of mycobacterial diseases.


15. Method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 11 or pharmaceutical composition according to claim 13.


16. A process for preparing a compound according to claim 1 characterized by a) reacting an intermediate of formula (II) with $H-R^{2a}$ or with a suitable salt form of $H-R^{2a}$, optionally in the presence of a suitable solvent and optionally in the presence of a suitable base



-80-


wherein W_1 represents a suitable leaving group, wherein R^{2a} represents alkoxy; a radical of

formula  wherein t and Z are defined as in claim 1; alkoxy substituted


with a radical of formula  wherein t and Z are defined as in claim 1;


mono or di(alkyl)amino wherein alkyl may optionally be substituted with one or two substituents each independently be selected from alkoxy or Ar or Het or morpholinyl or 2-oxopyrrolidinyl; and wherein R^1 , R^3 to R^7 , p, q and X are defined as in claim 1;

b) reacting an intermediate of formula (II) with R^{2b} -B(OH)₂ in the presence of a suitable catalyst, a suitable solvent, and a suitable base



10 wherein W_1 represents a suitable leaving group, wherein R^{2b} represents Het or alkyl and wherein R^1 , R^3 to R^7 , p, q and X are defined as in claim 1;


c) reacting an intermediate of formula (II) with  in the presence of a suitable catalyst, a suitable solvent and a suitable base,



15 wherein W_1 represents a suitable leaving group and wherein R^1 , R^3 to R^7 , p, q and X are defined as in claim 1;


d) reacting an intermediate of formula (III) with an intermediate of formula (IV) in the presence of a suitable coupling agent, in the presence of a suitable solvent and optionally in the presence of a suitable base,

-81-




wherein W_2 represents a suitable leaving group and wherein R^1 to R^7 , p and q are defined as in claim 1;


e) reacting an intermediate of formula (II) with a suitable acid in the presence of a suitable solvent,



wherein W_1 represents a suitable leaving group and wherein R^1 , R^3 to R^7 , p , q and X are defined as in claim 1;

f) converting a compound of formula (Ia-5) into a compound of formula (Ia-6), by


10 reaction with  in the presence of a suitable catalyst, a suitable solvent, and a suitable base,



wherein R^2 to R^7 , p , q and X are defined as in claim 1;

15 g) converting a compound of formula (Ia-5) into a compound of formula (Ia-7), by reaction with $\text{Sn}(\text{CH}_3)_4$ in the presence of a suitable catalyst and a suitable solvent,

-82-



wherein R^2 to R^7 , p , q and X are defined as in claim 1;

- or, if desired, converting compounds of formula (Ia) or (Ib) into each other following art-known transformations, and further, if desired, converting the compounds of formula (Ia) or (Ib), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, quaternary amines, tautomeric forms or *N*-oxide forms thereof.